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Background: Continuous flow left ventricular assist devices (LVADs) are increasingly used for patients with refractory heart failure. However, mid- 
and long-term outcomes of these devices are largely unknown.
Methods: We reviewed 91 patients who received LVAD therapy at Washington University in St. Louis from July 2004 through June 2009. Patients 
were classified as either pulsatile (PF) or continuous flow (CF), and evaluated for baseline risk factors, complications, and mortality.
Results: 56 HeartMate II, 17 VentrAssist ,15 HeartMate I, and 3 other devices were implanted during the study period with an increase in use of 
CF devices (Fig 1A). There were no differences between the PF and CF patients with respect to age, gender, HF etiology, and IABP use. Post-LVAD 
complications including reexploration for bleeding (27.8% vs. 20.5%), pneumonia (33.3% vs. 27.4%), permanent stroke (5.6% vs. 6.8%), and dialysis 
(11.1% vs. 8.2%) were comparable between groups. PF device patients had higher incidence of LVAD related infection (27.8% vs. 9.6%, p=0.041) 
and prolonged hospital stay (>22 days) (72.2% vs. 41.1%, p=0.018). Kaplan-Meier analysis revealed comparable mid-term survival in PF and CF 
groups (Fig 1B).
Conclusions: The advances in mechanical circulatory support with the use of smaller continuous flow devices have allowed for lower infection 
rates and comparable mid-term survival, when compared to pulsatile devices. Beyond 1.5 years, there is a trend towards improved outcomes with 
continuous flow devices.
